VTYX Ventyx Biosciences
- 1.950
- -0.130-6.25%
- 2.040
- +0.090+4.62%
Ventyx Biosciences News
Morgan Stanley Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ventyx Biosciences (VTYX)
Ventyx Biosciences Analyst Ratings
LifeSci Capital Maintains Ventyx Biosciences(VTYX.US) With Buy Rating
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $9
Ventyx Biosciences (VTYX) Receives a Buy From LifeSci Capital
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Maintains Target Price $10
LifeSci Capital Maintains Ventyx Biosciences(VTYX.US) With Buy Rating
LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)
Ventyx Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
Wells Fargo Maintains Overweight on Ventyx Biosciences, Lowers Price Target to $11
Ventyx Biosciences Analyst Ratings
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Ventyx Biosciences: A Buy Rating Backed by Promising Clinical Trials and Strong Financials
Ventyx Biosciences: A Cautious Hold Amid Intensifying Competition in Obesity Treatment Market
No Data